In keeping with observations from the single tumor CT26 model (Fig. 2), treatment with 25 μg CV8102 alone had no notable effect on injected or non-injected tumor growth; however, the combination with systemic anti-PD-1 antibodies led to stronger growth inhibition of both tumors than anti-PD-1 antibodies alone, resulting in 4/7 complete responders, and a 71% survival rate (Fig. 4d,e). Here, PDCD1 is linked to neoplasm.